Benjamin J. Frisch

Benjamin J. Frisch

Auto-generated profile, based on publicly available information

Benjamin J. Frisch

Department of Biomedical Engineering, University of Rochester, Rochester, NY, United States

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2012 in Blood
Verified
Journal Article
Open access
PDF file
BFBenjamin J. Frisch
Benjamin J. Frisch
JAJohn M. Ashton
John M. Ashton
LXLianping Xing
Lianping Xing
MBMichael W. Becker
Michael W. Becker
CJCraig T. Jordan
Craig T. Jordan
LCLaura Maria Calvi
Laura Maria Calvi
Pancytopenia is a major cause of morbidity in acute myeloid leukemia (AML), yet its cause is unclear. Normal osteoblastic cells have been shown to support hematopoiesis. To define the effects of leukemia on osteoblastic cells, we used an immunocompetent murine model of AML. Leukemic mice had inhibition of osteoblastic cells, with decreased serum levels of the bone formation marker osteocalcin. Osteoprogenitor cells and endosteal-lining osteopontin+ cells were reduced, and osteocalcin mRNA in CD45− marrow cells was diminished. This resulted in severe loss of mineralized bone. Osteoclasts were only transiently increased without significant increases in bone resorption, and their inhibition only partially rescued leukemia-induced bone loss. In vitro data suggested that a leukemia-derived secreted factor inhibited osteoblastic cells. Because the chemokine CCL-3 was recently reported to inhibit osteoblastic function in myeloma, we tested its expression in our model and in AML patients. Consistent with its potential novel role in leukemic-dependent bone loss, CCL-3 mRNA was significantly increased in malignant marrow cells from leukemic mice and from samples from AML patients. Based on these results, we propose that therapeutic mitigation of leukemia-induced uncoupling of osteoblastic and osteoclastic cells may represent a novel approach to promote normal hematopoiesis in patients with myeloid neoplasms.

16 May 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
BFBenjamin J. Frisch
Benjamin J. Frisch
CHCorey M. Hoffman
Corey M. Hoffman
SLSarah E. Latchney
Sarah E. Latchney
MLMark W. LaMere
Mark W. LaMere
JMJason Myers
Jason Myers
LCLaura Maria Calvi
Laura Maria Calvi
The bone marrow microenvironment contributes to the regulation of hematopoietic stem cell (HSC) function, though its role in age-associated lineage skewing is poorly understood. Here we show that dysfunction of aged marrow macrophages (Mφs) directs HSC platelet bias. Mφs from the marrow of aged mice and humans exhibited an activated phenotype, with increased expression of inflammatory signals. Aged marrow Mφs also displayed decreased phagocytic function. Senescent neutrophils, typically cleared by marrow Mφs, were markedly increased in aged mice, consistent with functional defects in Mφ phagocytosis and efferocytosis. In aged mice, interleukin-1B (IL-1B) was elevated in the bone marrow, and caspase-1 activity, which can process pro–IL-1B, was increased in marrow Mφs and neutrophils. Mechanistically, IL-1B signaling was necessary and sufficient to induce a platelet bias in HSCs. In young mice, depletion of phagocytic cell populations or loss of the efferocytic receptor Axl expanded platelet-biased HSCs. Our data support a model wherein increased inflammatory signals and decreased phagocytic function of aged marrow Mφs induce the acquisition of platelet bias in aged HSCs. This work highlights the instructive role of Mφs and IL-1B in the age-associated lineage skewing of HSCs, and reveals the therapeutic potential of their manipulation as antigeronic targets.

1 February 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
RPRebecca L. Porter
Rebecca L. Porter
MGMary A. Georger
Mary A. Georger
OBOlga Bromberg
Olga Bromberg
KMKathleen E. McGrath
Kathleen E. McGrath
BFBenjamin J. Frisch
Benjamin J. Frisch
LCLaura Maria Calvi
Laura Maria Calvi
Hematopoietic stem and progenitor cells (HSPCs), which continuously maintain all mature blood cells, are regulated within the marrow microenvironment. We previously reported that pharmacologic treatment of naïve mice with prostaglandin E2 (PGE2) expands HSPCs. However, the cellular mechanisms mediating this expansion remain unknown. Here, we demonstrate that PGE2 treatment in naïve mice inhibits apoptosis of HSPCs without changing their proliferation rate. In a murine model of sublethal total body irradiation (TBI), in which HSPCs are rapidly lost, treatment with a long-acting PGE2 analog (dmPGE2) reversed the apoptotic program initiated by TBI. dmPGE2 treatment in vivo decreased the loss of functional HSPCs following radiation injury, as demonstrated both phenotypically and by their increased reconstitution capacity. The antiapoptotic effect of dmPGE2 on HSPCs did not impair their ability to differentiate in vivo, resulting instead in improved hematopoietic recovery after TBI. dmPGE2 also increased microenvironmental cyclooxygenase-2 expression and expanded the α-smooth muscle actin-expressing subset of marrow macrophages, thus enhancing the bone marrow microenvironmental response to TBI. Therefore, in vivo treatment with PGE2 analogs may be particularly beneficial to HSPCs in the setting of injury by targeting them both directly and also through their niche. The current data provide rationale for in vivo manipulation of the HSPC pool as a strategy to improve recovery after myelosuppression.

12 July 2012 in Blood
Verified
Journal Article
Closed access
PDF file
OBOlga Bromberg
Olga Bromberg
BFBenjamin J. Frisch
Benjamin J. Frisch
JWJonathan M. Weber
Jonathan M. Weber
RPRebecca L. Porter
Rebecca L. Porter
RCRoberto Civitelli
Roberto Civitelli
LCLaura Maria Calvi
Laura Maria Calvi
Hematopoietic stem cell (HSC) regulation is highly dependent on interactions with the marrow microenvironment. Controversy exists on N-cadherin9s role in support of HSCs. Specifically, it is unknown whether microenvironmental N-cadherin is required for normal marrow microarchitecture and for hematopoiesis. To determine whether osteoblastic N-cadherin is required for HSC regulation, we used a genetic murine model in which deletion of Cdh2, the gene encoding N-cadherin, has been targeted to cells of the osteoblastic lineage. Targeted deletion of N-cadherin resulted in an age-dependent bone phenotype, ultimately characterized by decreased mineralized bone, but no difference in steady-state HSC numbers or function at any time tested, and normal recovery from myeloablative injury. Intermittent parathyroid hormone (PTH) treatment is well established as anabolic to bone and to increase marrow HSCs through microenvironmental interactions. Lack of osteoblastic N-cadherin did not block the bone anabolic or the HSC effects of PTH treatment. This report demonstrates that osteoblastic N-cadherin is not required for regulation of steady-state hematopoiesis, HSC response to myeloablation, or for rapid expansion of HSCs through intermittent treatment with PTH.

1 September 2006 in Bone
Verified
Journal Article
Closed access
JWJonathan M. Weber
Jonathan M. Weber
SFShaula R. Forsythe
Shaula R. Forsythe
CCChristina A. Christianson
Christina A. Christianson
BFBenjamin J. Frisch
Benjamin J. Frisch
BGBenjamin J. Gigliotti
Benjamin J. Gigliotti
LCLaura Maria Calvi
Laura Maria Calvi

4 February 2016 in Blood
Verified
Journal Article
Closed access
PDF file
SBSophia R. Balderman
Sophia R. Balderman
ALAllison J. Li
Allison J. Li
CHCorey M. Hoffman
Corey M. Hoffman
BFBenjamin J. Frisch
Benjamin J. Frisch
AGAlexandra N. Goodman
Alexandra N. Goodman
LCLaura Maria Calvi
Laura Maria Calvi
In vitro evidence suggests that the bone marrow microenvironment (BMME) is altered in myelodysplastic syndromes (MDSs). Here, we study the BMME in MDS in vivo using a transgenic murine model of MDS with hematopoietic expression of the translocation product NUP98-HOXD13 (NHD13). This model exhibits a prolonged period of cytopenias prior to transformation to leukemia and is therefore ideal to interrogate the role of the BMME in MDS. In this model, hematopoietic stem and progenitor cells (HSPCs) were decreased in NHD13 mice by flow cytometric analysis. The reduction in the total phenotypic HSPC pool in NHD13 mice was confirmed functionally with transplantation assays. Marrow microenvironmental cellular components of the NHD13 BMME were found to be abnormal, including increases in endothelial cells and in dysfunctional mesenchymal and osteoblastic populations, whereas megakaryocytes were decreased. Both CC chemokine ligand 3 and vascular endothelial growth factor, previously shown to be increased in human MDS, were increased in NHD13 mice. To assess whether the BMME contributes to disease progression in NHD13 mice, we performed transplantation of NHD13 marrow into NHD13 mice or their wild-type (WT) littermates. WT recipients as compared with NHD13 recipients of NHD13 marrow had a lower rate of the combined outcome of progression to leukemia and death. Moreover, hematopoietic function was superior in a WT BMME as compared with an NHD13 BMME. Our data therefore demonstrate a contributory role of the BMME to disease progression in MDS and support a therapeutic strategy whereby manipulation of the MDS microenvironment may improve hematopoietic function and overall survival. Key Points An in vivo model of MDS displays time-dependent defects in HSPCs and in microenvironmental populations. Normalization of the marrow microenvironment alters disease progression and transformation and improves hematopoietic function.